≡

Multiplex Assay Kit for Retinoschisin (RS) ,etc. by FLIA (Flow Luminescence Immunoassay)

RS1; XLRS1; Retinoschisis X-Linked,Juvenile 1; X-linked juvenile retinoschisis protein

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Retinoschisin (RS) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Retinoschisin (RS) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Retinoschisin (RS) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Retinoschisin (RS) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 81-99 96
EDTA plasma(n=5) 80-102 89
heparin plasma(n=5) 87-94 90

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Retinoschisin (RS) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Retinoschisin (RS) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Retinoschisin (RS) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 93-102% 80-91% 91-99% 89-102%
EDTA plasma(n=5) 82-96% 88-101% 87-101% 78-88%
heparin plasma(n=5) 91-99% 98-105% 96-103% 85-92%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:RS) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Hum Gene Ther Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis. PubMed: 22295905
IEEE Transactions on Magnetics Influence of Iron Oxide Nanoparticles on Innate and Genetically Modified Secretion Profiles of Mesenchymal Stem Cells Scholarsportal: Source
International Journal of Pharmaceutics A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases Pubmed:24576595
22 Structural recovery of the retina in a retinoschisin-deficient mouse after gene replacement therapy by solid lipid nanoparticles Pubmed:26986855
UBC Library Cell based therapeutics for retinal degenerations cIRcle:1.0303136
Molecular Vision An ex vivo gene therapy approach in X-linked retinoschisis pubmed:27390514
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPJ847Hu01 Recombinant Retinoschisin (RS) Positive Control; Immunogen; SDS-PAGE; WB.
PAJ847Hu01 Polyclonal Antibody to Retinoschisin (RS) WB
MAJ847Hu21 Monoclonal Antibody to Retinoschisin (RS) WB; IHC; ICC; IP.
SEJ847Hu ELISA Kit for Retinoschisin (RS) Enzyme-linked immunosorbent assay for Antigen Detection.
SCJ847Hu CLIA Kit for Retinoschisin (RS) Chemiluminescent immunoassay for Antigen Detection.
LMJ847Hu Multiplex Assay Kit for Retinoschisin (RS) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.